Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using CXCR1/2 Inhibitor SX-682

Review the clinical trials studying cxcr1/2 inhibitor sx-682 on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-7 of 7

Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
Status: Active
Location: 6 locations
Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: 6 locations
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Status: Active
Location: 3 locations
SX-682 with Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
SX-682 with Nivolumab for Maintenance Therapy in Patients with Unresectable, Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: University of Rochester, Rochester, New York
SX-682 in Combination with Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York